Exelixis (EXEL) – Investment Analysts’ Weekly Ratings Changes

Several analysts have recently updated their ratings and price targets for Exelixis (NASDAQ: EXEL):

• 1/8/2026 – Exelixis had its price target raised by analysts at HC Wainwright from $49.00 to $52.00. They now have a “buy” rating on the stock.
• 1/8/2026 – Exelixis had its “equal weight” rating reaffirmed by analysts at Morgan Stanley. They now have a $48.00 price target on the stock, up previously from $45.00.
• 1/5/2026 – Exelixis was downgraded by analysts at Citigroup Inc. from a “market outperform” rating to an “underperform” rating.
• 1/5/2026 – Exelixis was given a new $41.00 price target on by analysts at UBS Group AG.
• 1/5/2026 – Exelixis was downgraded by analysts at Bank of America Corporation from a “neutral” rating to an “underperform” rating. They now have a $41.00 price target on the stock.
• 12/18/2025 – Exelixis had its “market outperform” rating reaffirmed by analysts at Citigroup Inc..
• 12/14/2025 – Exelixis was upgraded by analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating.
• 12/6/2025 – Exelixis was downgraded by analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating.
• 11/18/2025 – Exelixis is now covered by analysts at Wolfe Research. They set a “peer perform” rating on the stock.

Insiders Place Their Bets

In related news, EVP Patrick J. Haley sold 34,187 shares of Exelixis stock in a transaction dated Thursday, November 20th. The stock was sold at an average price of $41.88, for a total value of $1,431,751.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Dana Aftab sold 48,383 shares of the business’s stock in a transaction that occurred on Tuesday, November 11th. The stock was sold at an average price of $42.50, for a total transaction of $2,056,277.50. Following the sale, the executive vice president directly owned 664,778 shares of the company’s stock, valued at approximately $28,253,065. This trade represents a 6.78% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 245,235 shares of company stock valued at $10,490,600. Corporate insiders own 2.85% of the company’s stock.

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.